KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2026)

Aquestive Therapeutics has reported Capital Expenditures over the past 9 years, most recently at -$425000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 543.94% year-over-year to -$425000.0; the TTM value through Dec 2025 reached $52000.0, down 33.33%, while the annual FY2025 figure was $52000.0, 33.33% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$425000.0 at Aquestive Therapeutics, down from $235000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $826000.0 in Q2 2023 and troughed at -$425000.0 in Q4 2025.
  • A 5-year average of $153100.0 and a median of $103500.0 in 2021 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 1350.0% in 2024 and later plummeted 543.94% in 2025.
  • Year by year, Capital Expenditures stood at $533000.0 in 2021, then plummeted by 95.12% to $26000.0 in 2022, then plummeted by 38.46% to $16000.0 in 2023, then crashed by 512.5% to -$66000.0 in 2024, then plummeted by 543.94% to -$425000.0 in 2025.
  • Business Quant data shows Capital Expenditures for AQST at -$425000.0 in Q4 2025, $235000.0 in Q3 2025, and $107000.0 in Q2 2025.